Discover
LRMR
Larimar Therapeutics, Inc.
3.21
2 x 2.32
2 x 3.89
bid
ask
+
0.16
5.25%
2 @ 07:05 AM
3.22 +0.01 (0.23%)
| Ytd | -15.75% | |
| 1y | 3.22% |
3.01
day range
3.25
2.71
52 week range
6.42
| Open | 3.05 | Prev Close | 3.05 | Low | 3.01 | High | 3.25 | Mkt Cap | 333.46M |
| Vol | 2.61M | Avg Vol | 2.06M | EPS | -2.12 | P/E | N/A | Forward P/E | -2.57 |
| Beta | 0.71 | Short Ratio | 5.19 | Inst. Own | 106.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.72 | 200-d Avg | 3.97 | 1yr Est | 20.41 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-10-30 | 2024-09 | -0.37 | -0.24 | 0.13 | 35.14% |
| 2024-08-07 | 2024-06 | -0.32 | -0.34 | -0.02 | -6.25% |
| 2024-05-09 | 2024-03 | -0.24 | -0.27 | -0.03 | -12.50% |
| 2024-03-14 | 2023-12 | -0.25 | -0.3 | -0.05 | -20.00% |
| 2023-11-14 | 2023-09 | -0.23 | -0.21 | 0.02 | 8.70% |
| 2023-08-10 | 2023-06 | -0.21 | -0.19 | 0.02 | 9.52% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-16 | Oppenheimer | Upgrade | Outperform | |
| 2024-10-03 | Wedbush | Upgrade | Outperform |
Profile
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-01-16 | BEN MAIMON CAROLE S | Chief Executive Officer | 332.95K | Stock Award(Grant) |
| 2024-01-16 | CELANO MICHAEL | Chief Financial Officer | 144.00K | Stock Award(Grant) |
| 2024-01-16 | CLAYTON RUSSELL | Officer | 22.50K | Stock Award(Grant) |
| 2024-02-15 | FLYNN JAMES E | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-02-15 | HAMILTON THOMAS EDWARD | Director | 724.23K | Purchase |
| 2024-01-16 | SHANKAR GOPI | Officer | 27.50K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Deerfield Management Company, L.P. (Series C) | 21.23M | 84.08M | 33.28% |
| 2024-09-29 | RA Capital Management, L.P. | 6.05M | 23.94M | 9.47% |
| 2024-09-29 | Janus Henderson Group PLC | 5.57M | 22.04M | 8.72% |
| 2024-09-29 | Goldman Sachs Group Inc | 4.25M | 16.83M | 6.66% |
| 2024-09-29 | Blue Owl Capital Holdings LP | 4.17M | 16.50M | 6.53% |
| 2024-09-29 | Blackrock Inc. | 2.97M | 11.77M | 4.66% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.34M | 5.31M | 2.10% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.10M | 4.34M | 1.72% |
| 2024-10-30 | Fidelity Advisor Biotechnology Fund | 524.80K | 2.08M | 0.82% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 510.24K | 2.02M | 0.80% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 431.07K | 1.71M | 0.68% |
| 2024-07-30 | Alger Fund-Small Cap Growth Fund | 398.96K | 1.58M | 0.63% |
Split
| Split | Date |
|---|---|
| 1 : 12 | 2020-05-29 |